Peptides in Canada: Understanding Health Canada Authorization, Clinical Research and Regulatory Status

Understanding peptides in canada requires separating scientific research, clinical investigation and regulatory authorization. Some peptide-based medicines have completed formal regulatory review, while other peptides remain investigational or are sold without Health Canada authorization. For international readers, Canada’s system provides a useful example of why research interest, clinical-trial activity, online availability and regulatory approval should never be treated as interchangeable.

Peptides occupy an unusual place in modern health and biomedical research.

Some peptide-based medicines have gone through formal regulatory review and are used within established medical practice. Other peptides are being investigated in clinical studies. Still others are discussed extensively online despite lacking authorization as therapeutic drugs.

Those categories are not interchangeable.

Canada provides a useful case study because its federal regulator, Health Canada, has established systems for drug authorization, clinical trials, manufacturing oversight and post-market surveillance—and has also taken increasingly visible action involving unauthorized peptide products.

For international readers, understanding the Canadian system can help clarify several questions that often become blurred online:

• What does it mean for a drug to be “authorized” in Canada?
• What is a Drug Identification Number, or DIN?
• What role do clinical trials play?
• Does authorization to conduct research mean a drug has been approved?
• What does Health Canada mean when it calls a peptide “unauthorized”?
• Where does BPC-157 currently fit?
• Can Canada’s regulatory position automatically be applied to the United States, Europe, Australia or another jurisdiction?

The short answer to the last question is no.

Drug regulation is jurisdiction-specific.

But the principles behind the Canadian system illustrate something broadly important:

Scientific interest, clinical investigation, product availability and regulatory authorization are four different things.

Understanding those distinctions is essential when evaluating emerging peptides.

Why understanding peptides in canada requires regulatory context

The word peptide describes a molecule composed of amino acids linked together.

That description alone tells us very little about a product’s regulatory status.

Peptide-based compounds can fall into very different regulatory situations.

A peptide may be:

• an established authorized medicine;
• a drug under clinical development;
• an investigational compound being studied preclinically;
• an active pharmaceutical ingredient;
• a substance discussed in scientific literature but not authorized for therapeutic use; or
• a product being promoted in ways that do not comply with the laws of a particular country.

So statements such as:

“Peptides are approved.”

or

“Peptides are not approved.”

are both too broad to be useful.

Regulators generally assess specific drug products for specific uses, supported by specific evidence and manufacturing information.

The appropriate regulatory question is therefore:

Has this particular drug product been authorized by the relevant regulator for sale or use in this jurisdiction?

In Canada, that regulator is Health Canada.

What Does Health Canada Actually Do?

Health Canada is the federal department responsible for regulating health products sold in Canada.

Its responsibilities include oversight of pharmaceutical drugs, biologic drugs, natural health products, medical devices and other regulated health products.

For drugs, the regulatory framework is designed around several broad considerations:

• safety;
• efficacy;
• quality;
• manufacturing standards;
• appropriate labelling;
• benefit-risk assessment; and
• continued monitoring after authorization.

Health Canada maintains public databases that allow healthcare professionals, researchers and consumers to verify the status of authorized products. The Drug Product Database, for example, contains information on drugs that Health Canada has authorized for sale.

This provides an important distinction that applies far beyond Canada:

A website listing is not a regulatory database.

A compound being available online does not establish that a regulator has evaluated and authorized it.

What Is a Canadian Drug Identification Number?

One of the most recognizable features of the Canadian drug regulatory system is the Drug Identification Number, commonly called a DIN.

Health Canada describes a DIN as an eight-digit number assigned to a drug product before it is marketed in Canada.

The number identifies specific characteristics of the authorized drug, including:

• manufacturer;
• product name;
• active ingredient or ingredients;
• strength;
• pharmaceutical form; and
• route of administration.

For authorized prescription and non-prescription drugs, the DIN appears on the product label.

This is more significant than simply assigning an identification code.

Health Canada explains that a DIN indicates that the product has undergone regulatory review and that its formulation, labelling and instructions for use have been evaluated.

Health Canada’s regulatory guidance further states that when a drug is authorized for marketing, the DIN reflects a determination that the product meets applicable requirements of the Food and Drugs Act and Food and Drug Regulations and has an acceptable benefit-risk profile for its authorized context.

A DIN Is Product-Specific

This point is easy to miss.

Authorization of one product containing a particular type of molecule does not automatically authorize every product containing a similar molecule.

A DIN is tied to specific characteristics.

That means regulators are not simply approving an abstract chemical name in isolation.

They evaluate a drug product in a defined regulatory context.

Factors can include:

• the active ingredient;
• concentration or strength;
• formulation;
• route of administration;
• intended use;
• manufacturing information;
• supporting evidence;
• labelling; and
• the identity of the manufacturer.

This helps explain why statements such as:

“This ingredient exists in an authorized drug, therefore every version is authorized.”

can be misleading.

Regulatory authorization generally applies to the authorized product and conditions associated with that authorization.

What Is a Notice of Compliance?

For certain drugs—particularly products treated as “new drugs” under Canada’s regulatory framework—the regulatory process also involves a Notice of Compliance, or NOC.

Health Canada describes an NOC as something issued to a manufacturer following satisfactory review of a new drug submission.

The NOC signifies that the submission complies with applicable requirements of the Food and Drug Regulations.

This creates another useful distinction.

A DIN identifies the authorized drug product.

A Notice of Compliance reflects the successful review of an applicable new-drug submission.

Depending on the regulatory pathway, an authorized Canadian drug may therefore have both an NOC and a DIN.

How Does a Drug Move Toward Authorization in Canada?

The exact pathway varies depending on the type of product, but the general development process follows a recognizable progression.

Health Canada describes the pre-market process as involving:

• preclinical studies;
• clinical trials;
• a regulatory product submission;
• Health Canada’s review of that submission; and
• a market-authorization decision.

Each stage answers a different question.

Stage 1: Preclinical Research

Before a new compound is widely investigated in people, researchers typically conduct laboratory and animal studies.

These studies can explore questions involving:

• biological mechanism;
• toxicity;
• pharmacology;
• distribution within the body;
• dose-response relationships; and
• possible therapeutic effects.

Preclinical research is valuable.

But it is not equivalent to proof that the compound works safely and effectively in humans.

Animal findings may justify human investigation.

They do not replace it.

This point is particularly relevant to experimental peptides such as BPC-157, because much of the literature surrounding proposed recovery effects remains preclinical. Readers interested in that evidence specifically can review BPC-157 Recovery Claims: What Human Evidence Actually Exists?.

Stage 2: Clinical Trials

Clinical trials investigate drugs in human participants.

They may examine questions such as:

• how a compound behaves in humans;
• what exposure levels occur after administration;
• possible adverse effects;
• whether a biological effect is observed;
• whether symptoms or clinical outcomes improve; and
• how the investigational drug compares with placebo or another treatment.

Clinical development is often discussed in phases, although actual programs can vary.

Early studies commonly place more emphasis on safety, tolerability and pharmacokinetics.

Later trials may evaluate therapeutic effectiveness in larger patient populations.

The crucial point is that:

Participation in clinical research does not mean the investigational drug has already been authorized for routine therapeutic use.

Research exists precisely because important questions remain unanswered.

Health Canada Authorization to Conduct a Clinical Trial Is Not Market Authorization

This is one of the most important concepts in the entire regulatory discussion.

Before most drug clinical trials can be conducted in Canada, the sponsor submits a Clinical Trial Application, or CTA, to Health Canada.

Health Canada reviews the application with objectives that include protecting participants, reducing foreseeable risks and ensuring that the proposed study can appropriately address its research goals. Clinical trials must also meet Canadian regulatory requirements and good clinical practice standards.

But Health Canada allowing a clinical trial to proceed does not mean:

• the investigational drug has been approved as a treatment;
• its effectiveness has been established;
• its long-term safety has been demonstrated;
• its proposed indication has been accepted; or
• the drug can automatically be marketed to the public.

Trial authorization and market authorization answer different regulatory questions.

A clinical trial asks, in effect:

Can this investigational study proceed under the required safeguards?

A market authorization asks a much broader question:

Has sufficient evidence and product information been submitted to support authorization of this drug for its proposed use?

Confusing those two stages can make an early experimental treatment look much more established than it actually is.

A Registered Trial Is Not an Approved Treatment Either

Another common source of confusion arises when an investigational compound appears in a clinical-trial registry.

A registered trial demonstrates that a study has been recorded.

It does not automatically establish that:

• the trial was completed;
• the final results were favourable;
• the findings were published;
• another research group replicated them;
• regulators accepted the conclusions; or
• the drug subsequently received market authorization.

This distinction matters because clinical-trial registrations are sometimes cited online as evidence that an experimental peptide is “clinically proven.”

That inference is not justified.

The appropriate questions are:

Was the trial completed?

What were the results?

Were they published or otherwise publicly reported?

What endpoints were measured?

Was the study sufficiently large and well controlled?

Did regulators subsequently authorize the drug?

The existence of a study is evidence of research activity.

It is not, by itself, evidence of therapeutic effectiveness.

Health Canada has also increased requirements around clinical-trial registration and public disclosure of results, reflecting the broader importance of transparency in interpreting clinical research. Updated Canadian guidance on trial registration and disclosure took effect in July 2026.

Stage 3: The Regulatory Submission

Clinical evidence does not automatically transform itself into regulatory authorization.

A sponsor seeking permission to market a new drug generally must submit an appropriate regulatory dossier to Health Canada.

Depending on the pathway, the submission can contain extensive information involving:

• quality and chemistry;
• manufacturing;
• non-clinical studies;
• clinical trial findings;
• proposed indications;
• dosage and administration;
• contraindications and warnings;
• adverse-event information;
• product labelling; and
• overall benefit-risk assessment.

Health Canada then evaluates the submitted information.

A favourable research paper and regulatory approval are therefore not the same milestone.

A regulator considers a broader evidence package than simply whether one study produced an encouraging result.

Stage 4: Market Authorization

If the applicable regulatory requirements are met, Health Canada may grant market authorization.

For drugs requiring a DIN, Health Canada assigns the eight-digit Drug Identification Number associated with that authorized product.

For applicable new drugs, a Notice of Compliance is also issued following satisfactory review.

Authorized drugs can then be verified through Health Canada’s public databases.

The Drug Product Database is therefore particularly useful because it allows people to check whether a drug has actually reached the authorization stage rather than relying on marketing terminology.

Authorization Is Not the End of Regulation

Drug regulation also continues after a product reaches the market.

Post-market systems can involve:

• adverse-event monitoring;
• safety communications;
• recalls;
• inspections;
• manufacturing oversight;
• labelling changes;
• product monograph updates; and
• regulatory action when new safety information emerges.

This matters because regulatory approval does not mean that uncertainty disappears.

Instead, it means regulators have concluded that the evidence available supports authorization under specific conditions while monitoring continues.

So What Does “Unauthorized Drug” Mean in Canada?

In Canadian regulatory language, an unauthorized drug is not simply a drug that Health Canada “doesn’t like.”

It refers to a product that does not have the required authorization for sale under the applicable Canadian framework.

Health Canada states that a drug product that requires a DIN and is sold without one is not compliant with Canadian law.

For unauthorized peptide products, Health Canada’s concern extends beyond the absence of an identification number.

The regulator has emphasized that unauthorized products have not undergone its required assessment for:

• safety;
• efficacy; and
• quality.

That distinction matters.

“Unauthorized” should not automatically be translated into:

“Scientists have proven this molecule has no biological effect.”

Those statements are very different.

Instead, the regulatory meaning is closer to:

This product has not received the required Health Canada authorization to be sold for the represented drug use in Canada.

Scientific uncertainty and regulatory status overlap, but they are not identical concepts.

Health Canada’s 2026 Warning About Injectable Peptides

The Canadian regulatory landscape became especially visible in 2026.

On April 9, 2026, Health Canada issued a national public advisory concerning unauthorized injectable peptide drugs sold online.

The regulator specifically listed a number of peptides among examples of unauthorized products it had seized, including:

• BPC-157;
• CJC-1295;
• GHK-Cu;
• ipamorelin;
• KPV;
• MOTS-C;
• SS-31;
• TB-500;
• retatrutide; and
• others.

Health Canada stated that peptides are generally regulated as prescription drugs in Canada and that unauthorized peptide drugs had not been assessed by the regulator for safety, efficacy and quality.

That language is particularly important for international readers.

The advisory is a statement about Canadian regulatory status and Canadian law.

It should not automatically be rewritten as:

“Every one of these molecules is illegal everywhere.”

Regulatory classifications differ between jurisdictions.

For a broader discussion of Canada’s regulatory framework and how it applies to peptide research, see Peptides in Canada: Health Canada Approval and Research Guide.

“For Research Use Only” Does Not Create a Canadian Regulatory Exemption for Human Use

Products involving experimental peptides are sometimes labelled:

“For Research Use Only”

or

“Not for Human Consumption.”

The existence of that wording can create confusion about regulatory status.

Health Canada has addressed the issue directly.

Its April 2026 peptide advisory states that it continues to identify peptide products carrying this type of research-only labelling and that such wording does not make the products legal or exempt them from regulatory requirements when they are being sold or represented in ways captured by Canadian drug law.

Health Canada repeats this position in its public information concerning bodybuilding products.

This provides another useful principle:

A disclaimer does not necessarily determine a product’s regulatory classification.

Regulators can consider what the product is, how it is represented and the circumstances under which it is sold.

BPC-157 as a Case Study

BPC-157 illustrates many of these distinctions particularly well.

The peptide has been investigated extensively in animal and laboratory research, with studies exploring areas such as:

• tissue injury;
• gastrointestinal effects;
• vascular signalling;
• tendon and ligament models;
• muscle injury;
• inflammatory processes; and
• other experimental biological effects.

Published human evidence exists but remains limited.

That scientific situation is separate from the Canadian regulatory situation.

Health Canada has explicitly identified BPC-157 among examples of unauthorized injectable peptide drugs seized in Canada.

In May 2026, Health Canada’s recalls database also listed BPC-157 powder in a recall involving unauthorized active pharmaceutical ingredients.

These regulatory actions should not be interpreted as a scientific statement that researchers are forbidden from studying BPC-157.

They mean that the products involved did not have the required authorization within the Canadian regulatory context.

That is a critical distinction.

Readers interested in the human evidence behind recovery-related claims can also review our evidence review of BPC-157 recovery claims.

Research Can Continue Even When a Drug Is Not Authorized for Routine Use

An experimental compound does not need to be a marketed medicine before researchers can investigate it.

If that were the case, new medicines could never be developed.

Instead, drug development intentionally creates a separation between:

investigational use

and

routine marketed use.

Researchers study investigational compounds under controlled protocols because their benefits and risks remain uncertain.

If a development program eventually generates adequate evidence, the sponsor can pursue regulatory authorization.

If it does not, the drug may remain investigational.

Therefore:

“Not authorized as a marketed drug” does not mean “cannot be researched.”

And conversely:

“Being researched” does not mean “authorized as a marketed drug.”

Both statements can be true at the same time.

Research Interest Does Not Equal Health Canada Approval

This point deserves emphasis because emerging peptides often attract attention well before clinical development is mature.

A compound may have:

• dozens of animal studies;
• published mechanistic papers;
• a registered clinical trial;
• early human observations;
• discussion among physicians or researchers;
• extensive social-media attention; and
• substantial public interest,

while still lacking regulatory authorization for therapeutic marketing.

Regulatory authorization depends on the relevant evidence package meeting regulatory requirements.

Popularity is not part of that evidence hierarchy.

Neither is the number of social-media posts discussing the molecule.

What Health Canada’s Enforcement Activity Tells Us

Canada’s recent peptide enforcement provides a practical example of how these regulations operate.

Health Canada has reported seizures and enforcement actions involving unauthorized peptide products at multiple Canadian locations and online sellers.

In July 2026, Health Canada announced that the Superior Court of Québec had granted a permanent injunction against Canlab Research and its representatives, preventing the company from selling unauthorized injectable peptides in Canada.

Health Canada stated that the company had marketed unauthorized peptide drugs with unproven health claims despite previous regulatory actions.

This demonstrates that Canadian regulation is not limited to publishing guidance documents.

The regulator can use measures that include:

• product seizures;
• public advisories;
• border action;
• recalls;
• compliance measures; and
• court proceedings.

Health Canada has also stated that it works with the Canada Border Services Agency concerning unauthorized health products entering Canada.

Authorization, Evidence and Quality Are Different Questions

When assessing an emerging peptide, it is useful to ask three separate questions.

Question 1: Is there evidence of biological activity?

This may be answered initially through laboratory, animal or early human research.

Question 2: Is there adequate evidence of clinical safety and effectiveness for a particular use?

That requires stronger human clinical evidence.

Question 3: Has the actual drug product received authorization from the regulator in the jurisdiction where it is being marketed?

That is a regulatory question.

The answers may differ.

A peptide might have compelling preclinical data but no established clinical efficacy.

Another could have human research but no market authorization.

Another could have authorization for one indication but not for unrelated claims.

These distinctions prevent scientific evidence from being overstated.

Approved for One Purpose Does Not Mean Proven for Another

Regulatory authorization is also tied to indications.

Suppose a drug were eventually authorized for one narrowly defined medical condition.

That would not automatically demonstrate effectiveness for:

• sports recovery;
• anti-aging;
• muscle growth;
• tendon injury;
• cognitive enhancement;
• weight management; or
• another unrelated purpose.

Each therapeutic claim requires evidence.

This is particularly important with peptides because the same molecule may be discussed across very different online communities, sometimes with entirely different proposed benefits.

A scientific effect observed in one tissue does not prove effectiveness throughout the body.

A benefit observed for one disease does not establish effectiveness for another.

Regulatory authorization must therefore be interpreted precisely.

Does the DIN Tell You Everything About a Drug?

No.

A DIN is a useful confirmation that Health Canada has authorized the drug product, but serious evaluation should still look at:

• the authorized indication;
• product monograph;
• route of administration;
• contraindications;
• warnings;
• dosing instructions;
• adverse effects; and
• patient population.

Health Canada’s Drug Product Database provides access to product information and, for many human drugs, associated product monographs.

The regulatory question should therefore not stop at:

“Does this drug have a DIN?”

It should continue with:

“What exactly has Health Canada authorized this drug to be used for?”

Canada Is Only One Regulatory Jurisdiction

BodyTechPharma.com serves an international readership, so another distinction is essential.

Health Canada’s decisions apply within the Canadian regulatory framework.

Other jurisdictions use their own laws, review processes, classifications and regulatory agencies.

Examples include:

• the U.S. Food and Drug Administration in the United States;
• the European Medicines Agency together with national authorities within Europe;
• the Medicines and Healthcare products Regulatory Agency in the United Kingdom;
• the Therapeutic Goods Administration in Australia; and
• other national health and medicines regulators around the world.

A drug’s status may therefore differ by country.

A product authorized in one jurisdiction is not automatically authorized in another.

Likewise, terminology such as:

• approved;
• authorized;
• licensed;
• registered;
• investigational;
• prescription-only; or
• unauthorized

can have specific meanings under different national systems.

Readers should therefore verify regulatory status directly with the authority responsible for medicines in their own country.

Do Not Infer International Legality From a Canadian Article

This is especially important when reading news about enforcement.

If Health Canada says that a specific peptide product is unauthorized in Canada, that is strong evidence about its Canadian regulatory status.

It does not, by itself, determine:

• U.S. law;
• UK law;
• European Union law;
• Australian law;
• import rules in another country;
• prescribing rules elsewhere; or
• the policies of individual sporting organizations.

International readers should therefore avoid treating Canadian regulatory statements as universal legal conclusions.

The same principle works in reverse.

FDA status in the United States does not automatically establish Health Canada status.

European authorization does not automatically create Canadian authorization.

Regulatory claims should always name the jurisdiction.

A Useful Checklist for Evaluating Peptide Claims

1. What type of evidence is being cited?

Is it:

• cell research;
• an animal study;
• a case report;
• an uncontrolled human study;
• a randomized trial;
• a systematic review; or
• a regulatory review?

These forms of evidence do not carry equal weight.

2. Was the research conducted in humans?

Animal evidence can support a hypothesis but cannot prove human therapeutic effectiveness.

3. What outcome was actually measured?

A biological marker is not necessarily the same as improved symptoms, function or long-term clinical outcomes.

4. Was there a comparison group?

Without one, causal conclusions become much more difficult.

5. Has the result been independently replicated?

One study rarely settles a scientific question.

6. Has the relevant regulator authorized the product?

For Canada, check Health Canada’s Drug Product Database and related regulatory information.

7. What indication was authorized?

Do not extrapolate authorization for one condition into unrelated claims.

8. Is someone treating clinical-trial activity as though it were regulatory approval?

If so, that is a major warning sign.

9. Which country’s rules actually apply?

Regulatory statements should always be interpreted in the correct jurisdiction.

Readers looking for product-specific information can view BodyTechPharma’s BPC-157 10mg product page. The presence of a product reference does not imply Health Canada authorization, therapeutic approval or demonstrated clinical effectiveness, and the regulatory and scientific distinctions discussed throughout this article should remain separate from product information.

What International Readers Should Take Away From Canada’s Approach

Canada’s peptide regulatory landscape illustrates a broader principle that applies to emerging health technologies everywhere.

Research is not regulation.

Preclinical research can show that a compound deserves further investigation.

Clinical research can begin answering questions about how the compound behaves in humans.

A clinical-trial authorization can allow investigators to conduct a study under regulatory safeguards.

A registered trial can document that the study exists.

Published results can contribute to the scientific evidence base.

But none of those milestones automatically equals market authorization.

In Canada, Health Canada evaluates drug products under federal law, and authorized drugs generally receive identifying regulatory information such as a DIN. New drugs may also receive a Notice of Compliance following satisfactory regulatory review.

At the same time, Health Canada has explicitly warned about unauthorized injectable peptide drugs and has specifically identified BPC-157 in recent advisories and enforcement-related actions.

The most important lesson is therefore not that all peptides belong in one regulatory category.

They do not.

The lesson is that each molecule, each product, each claimed use and each jurisdiction needs to be evaluated separately.

Bottom Line

The Canadian regulatory system provides a structured way to distinguish between scientific investigation and authorized medical use.

In simplified terms:

Preclinical research asks whether a compound is worth investigating.

Clinical research asks what happens when it is studied in humans.

Regulatory review asks whether the complete evidence and product information support authorization.

A DIN identifies a drug product that Health Canada has authorized for sale in Canada under the applicable regulatory framework.

These are sequential but distinct concepts.

For experimental peptides such as BPC-157, research interest should not be interpreted as evidence of Canadian market authorization.

Health Canada has specifically identified BPC-157 among unauthorized injectable peptide drugs encountered in Canada, while scientific investigations into the peptide continue.

Both facts can coexist.

For international readers, the final principle is equally important:

Do not assume Canada’s regulatory classification automatically applies in another country.

Check the regulator responsible for medicines in your own jurisdiction and distinguish carefully between:

research activity, clinical evidence, regulatory authorization and marketing claims.

That distinction is one of the most reliable ways to evaluate emerging peptide information accurately.

Frequently Asked Questions

Are peptides legal in Canada?

There is no single regulatory status that applies to every peptide. Some peptide-based drug products are authorized by Health Canada, while others remain investigational or are sold without the required authorization. The status of the specific product, formulation, route and intended use must be checked individually.

What does a DIN mean for a peptide drug in Canada?

A Drug Identification Number is an eight-digit identifier assigned by Health Canada to an authorized drug product. It is product-specific and reflects details such as the manufacturer, active ingredient, strength, dosage form and route of administration.

Does a Canadian clinical trial mean a peptide has been approved?

No. Authorization to conduct a clinical trial allows an investigational drug to be studied under defined regulatory safeguards, but it does not amount to market authorization. The drug’s safety, effectiveness and overall benefit-risk profile may still be under investigation.

What does Health Canada mean when it calls a peptide product unauthorized?

It means the product has not received the required authorization for sale as a drug under the applicable Canadian regulatory framework. It does not necessarily mean that the underlying molecule has no biological activity or cannot be investigated scientifically.

Does “for research use only” exempt a peptide from Canadian drug rules?

No automatic exemption is created simply by using that wording. Health Canada has stated that research-use-only or not-for-human-consumption labelling does not necessarily place a product outside Canadian regulatory requirements when the product’s nature, presentation and sale bring it within drug regulation.

Does Health Canada’s position on BPC-157 apply everywhere in the world?

No. Health Canada’s position determines Canadian regulatory status, not the law or authorization status in every other country. International readers should verify BPC-157 and other peptide products with the regulator responsible for medicines in their own jurisdiction.

References and Further Reading

• Health Canada. Drug Identification Number (DIN). Explains the eight-digit identifier assigned to authorized drug products and its relationship to Canadian market authorization.
• Health Canada. Drug Product Database. Searchable database containing drugs authorized for sale by Health Canada.
• Health Canada. Regulatory Requirements for Drug Identification Numbers. Guidance concerning DIN requirements and market authorization.
• Health Canada. Notice of Compliance Database. Explains NOCs issued following satisfactory review of submissions for new drugs.
• Health Canada. Clinical Trials and Drug Safety. Describes the role of preclinical studies, clinical trials, regulatory submissions and market-authorization decisions.
• Health Canada. Guidance Document for Clinical Trial Sponsors: Clinical Trial Applications. Canadian requirements for authorization and conduct of drug clinical trials.
• Health Canada. Guidance on the Registration of Clinical Trials and Public Disclosure of Results. Updated guidance effective July 29, 2026.
• Health Canada. Think Twice Before Injecting Peptides Bought Online: Unauthorized Products Can Seriously Harm You. April 9, 2026 public advisory identifying BPC-157 and other unauthorized injectable peptide drugs.
• Health Canada. Using Bodybuilding Products. Regulatory and safety information concerning unauthorized peptide products and other substances.
• Health Canada. Unauthorized Injectable Peptide Drugs Seized and Sold by Canada Peptide May Pose Serious Health Risks. Canadian enforcement advisory identifying multiple unauthorized peptide drugs, including BPC-157.
• Health Canada. GHK-Cu & BPC-157 Powder: Unauthorized Active Pharmaceutical Ingredients. May 2026 recall notice.
• Health Canada. Health Canada Obtains Permanent Injunction Preventing Canlab Research’s Illegal Sale of Injectable Peptides in Canada. July 29, 2026.